- Home
- ZEPP vs QNCX Comparison
ZEPP vs QNCX Comparison
Compare ZEPP & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZEPP
- QNCX
- Stock Information
- Founded
- ZEPP 2013
- QNCX 2012
- Country
- ZEPP Netherlands
- QNCX United States
- Employees
- ZEPP N/A
- QNCX N/A
- Industry
- ZEPP Computer Manufacturing
- QNCX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ZEPP Technology
- QNCX Health Care
- Exchange
- ZEPP Nasdaq
- QNCX Nasdaq
- Market Cap
- ZEPP 37.1M
- QNCX 43.2M
- IPO Year
- ZEPP N/A
- QNCX 2019
- Fundamental
- Price
- ZEPP $2.36
- QNCX $1.06
- Analyst Decision
- ZEPP
- QNCX Strong Buy
- Analyst Count
- ZEPP 0
- QNCX 5
- Target Price
- ZEPP N/A
- QNCX $8.00
- AVG Volume (30 Days)
- ZEPP 33.4K
- QNCX 611.7K
- Earning Date
- ZEPP 05-19-2025
- QNCX 05-13-2025
- Dividend Yield
- ZEPP N/A
- QNCX N/A
- EPS Growth
- ZEPP N/A
- QNCX N/A
- EPS
- ZEPP N/A
- QNCX N/A
- Revenue
- ZEPP $181,183,000.00
- QNCX N/A
- Revenue This Year
- ZEPP $758.69
- QNCX N/A
- Revenue Next Year
- ZEPP N/A
- QNCX N/A
- P/E Ratio
- ZEPP N/A
- QNCX N/A
- Revenue Growth
- ZEPP N/A
- QNCX N/A
- 52 Week Low
- ZEPP $2.06
- QNCX $0.51
- 52 Week High
- ZEPP $4.38
- QNCX $2.45
- Technical
- Relative Strength Index (RSI)
- ZEPP 39.20
- QNCX 51.30
- Support Level
- ZEPP $2.35
- QNCX $1.01
- Resistance Level
- ZEPP $2.61
- QNCX $1.06
- Average True Range (ATR)
- ZEPP 0.22
- QNCX 0.11
- MACD
- ZEPP -0.03
- QNCX 0.02
- Stochastic Oscillator
- ZEPP 18.05
- QNCX 80.95
About ZEPP Zepp Health Corporation
Zepp Health Corp is engaged in the business of manufacturing smart health wearable products. The company operates in two segments: Xiaomi Wearable Products and Self-branded products & others. The product portfolio includes smartwatches and fitness bands. The majority is from Self-branded products & other segments. It generates majority of the revenue from Xiaomi Wearable Products segment.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.